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Prostate cancer (PCa) is currently the most
common cancer in men, accounting for 29%
of all new cases of cancer (Jemal et al. 2007).
The etiology of PCa in humans is complex
and may include age, race, and environmental
and lifestyle risk factors, among other factors.
The environmental factors such as exposure
to cadmium that contribute to this disease
have been less well studied than the afore-
mentioned factors. Yet, there is epidemiologic
and experimental evidence for a potential
association between Cd exposure and PCa in
humans and rodents (Goyer et al. 2004;
Vinceti et al. 2007; Waalkes et al. 1989).
Cd is classiﬁed as a human carcinogen by
the International Agency for Research on
Cancer (IARC 1993) and the National
Toxicology Program (NTP 2004). It is ubiq-
uitously present in the environment because
of industrial and other types of pollution.
Occupational exposures are related to handling
of waste associated with mining, smelting,
electroplating, and manufacturing of batter-
ies, pigments, and plastics (IARC 1993;
NTP 2004). In contaminated areas, Cd per-
meates the soil and water supply, reaching
levels as high as 0.21 mg/kg and approximately
1.9 µM in foodstuffs (Yan et al. 2007).
Smokers are also exposed to Cd from ciga-
rettes. In general, the main route of Cd expo-
sure among nonsmokers is food intake
(Satarug and Moore 2004). Human exposure
is of serious concern in fast-developing coun-
tries such as China and India that have less
stringent regulations (Govil et alet al. 2007;
Sun et al. 2006; Yan et al. 2007). In humans,
Cd is associated with lung cancer but is not
definitively linked to PCa, although Cd can
induce PCa in rodents (Waalkes et al. 1989).
Because of its very slow excretion rates
(~ 0.001%/day) (Satarug and Moore 2004),
Cd accumulates in men as they age (Baecklund
et al. 1999), and the prostate is one of the
organs of the body with high bioaccumulation
of Cd (0.45–28 µM) (Achanzar et al. 2001;
Lindegaard et al. 1990). Patients with PCa
appear to have higher circulating and organ
levels of Cd (Brys et al. 1997).
Cd exposure has been reported to cause
neoplastic transformation of human prostatic
epithelial cells; however, the efficacy of this
transformation is highly dependent on the
dose of the metal ion (Achanzar et al. 2001;
Nakamura et al. 2002). Exposure of normal
human prostate epithelial cells to 10 µM Cd
transiently increased the expression of p53,
c-myc, and c-jun after 2 hr as a prelude to
apoptosis (Achanzar et al. 2000). Longer
exposure to 10 µM Cd resulted in the emer-
gence of malignant phenotypes, including
resistance to apoptosis, increased cell
proliferation rate, disruption in DNA repair
mechanisms, broad-based changes in gene
expression, and epigenetic alterations (Goyer
et al. 2004). 
We are particularly interested in the contri-
bution of noncytotoxic, low doses (< 10 µM)
of Cd to neoplastic transformation of human
prostate epithelial cells because of the relevance
to environmental health. In this study we
investigated the effects of low, noncytotoxic
doses of Cd on the growth, cell-cycle distribu-
tion, and gene expression of an immortalized
human normal prostate epithelial cell line
(NPrEC). We found that low doses of Cd pro-
moted growth in NPrEC cells and that
2.5 µM Cd induced overexpression of a set of
genes all linked to tumor necrosis factor-α
[TNFα; Entrez Gene ID 7124 (National
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BACKGROUND: Cadmium is implicated in prostate carcinogenesis, but its oncogenic action remains
unclear. 
OBJECTIVES: In this study we aimed to decipher changes in cell growth and the transcriptome in an
immortalized human normal prostate epithelial cell line (NPrEC) following exposure to low-dose Cd.
METHODS: Synchronized NPrEC cells were exposed to different doses of Cd and assayed for cell
viability and cell-cycle progression. We investigated changes in transcriptome by global proﬁling
and used Ingenuity Pathways Analysis software to develop propositions about functional connec-
tions among differentially expressed genes. A neutralizing antibody was used to negate the effect of
Cd-induced up-regulation of tumor necrosis factor (TNF) in NPrEC cells.
RESULTS: Exposure of NPrEC to 2.5 µM Cd enhanced cell viability and accelerated cell-cycle pro-
gression. Global expression proﬁling identiﬁed 48 genes that exhibited ≥ 1.5-fold changes in expres-
sion after 4, 8, 16, and 32 hr of Cd treatment. Pathway analyses inferred a functional connection
among 35 of these genes in one major network, with TNF as the most prominent node. Fourteen of
the 35 genes are related to TNF, and 11 exhibited an average of > 2-fold changes in gene expression.
Real-time reverse transcriptase-polymerase chain reaction conﬁrmed the up-regulation of 7 of the
11 genes (ADAM8, EDN1, IL8, IL24, IL13RA2, COX2/PTGS2, and SERPINB2) and uncovered a
28-fold transient increase in TNF expression in Cd-treated NPrEC cells. A TNF-neutralizing anti-
body effectively blocked Cd-induced elevations in the expression of these genes.
CONCLUSIONS: Noncytotoxic, low-dose Cd has growth-promoting effects on NPrEC cells and
induces transient overexpression of TNF, leading to up-regulation of genes with oncogenic and
immunomodulation functions.
KEY WORDS: carcinogenesis, cytokine, global expression proﬁling, heavy metals, immune response,
inflammation, Ingenuity Pathway Analysis, knowledge-based analysis, prostate cancer. Environ
Health Perspect 116:769–776 (2008). doi:10.1289/ehp.11215 available via http://dx.doi.org/
[Online 3 March 2008]2008a)], which exhibited a transient but dras-
tic up-regulation after Cd exposure. These
genes are related primarily to inflammation,
immunomodulation, and oncogenesis. These
ﬁndings suggested that Cd can directly trigger
a proinﬂammatory/pro-oncogenic response in
normal prostatic epithelial cells in the absence
of paracrine signals from the stroma.
Materials and Methods
Cell culture. The NPrEC cell line, which
shows a basal epithelial cell phenotype, was
established in our laboratory (Mobley et al.
2003). The cells were grown in Defined
Keratinocyte-SFM medium (Invitrogen,
Carlsbad, CA) with growth-promoting supple-
ment. Cell cultures were maintained at 37°C
in a humidified incubator with a 5% CO2
atmosphere. 
Cell-viability assay. We seeded 5 × 103
NPrEC cells in each well of a 96-well plate in
quadruplicate. After 72 hr, the medium was
replaced with 200 µL of fresh medium con-
taining 0, 1, 2.5, 5, 10, or 20 µM cadmium
chloride. Cell viability was determined after
24, 48, and 72 hr of treatment by the CellTiter
96 Aqueous One Solution Cell Proliferation
Assay [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS)] kit (Promega,
Madison, WI). 
Cell-cycle analysis. NPrEC cells were
seeded at 8 × 105 cells per 75-cm2 flask and
synchronized by maintaining the cells in
medium without supplement for 72 hr. The
medium was then replaced with medium that
included the supplement to induce synchro-
nized growth (0 hr time point) and then
treated or not treated with 2.5 µM CdCl2 for
4, 8, 16, or 32 hr. Flow cytometry was per-
formed twice as described previously
(Wetherill et al. 2002). 
RNA isolation. We extracted total RNA
from NPrEC cells with TRIzol reagent
(Invitrogen) according to the manufacturer’s
instructions. RNA quality was assessed by the
absorbance ratio at 260/280 nm and gel elec-
trophoresis before further analysis. 
Global transcriptional proﬁling. We per-
formed global transcriptional analysis using the
Human Expression Array U133 Plus 2.0 arrays
(Affymetrix, Santa Clara, CA), which have
54,675 probe sets. Sample preparation for
array hybridization was carried out with One-
Cycle Target Labeling and Control Reagents
(Affymetrix). After fragmentation, the biotiny-
lated cRNA was hybridized to arrays at 45°C
for 16 hr. The arrays were then washed,
stained with streptavidin-phycoerythrin, and
scanned with a probe array scanner. Images of
the scanned chips were analyzed with the
Affymetrix GeneChip Operating System.
Hybridization intensity data were converted
into a presence/absence/marginal call for each
gene, and changes in gene expression between
experiments were detected by comparison
analysis. 
Transcriptome data analyses. The data
reported here have been deposited in NCBIs
Gene Expression Omnibus (Barrett et al.
2006) and are accessible through accession no.
GSE9951 (National Center for Biotechnology
Information 2008b). Microarray analyses were
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Table 1. Genes expressed differentially at four time points in NPrEC cells treated with 2.5 µM CdCl2.
IDa  Gene 4 hr 8 hr 16 hr 32 hr Mean Networkb
81611 ANP32E –3.01 –3.56 –3.46 –2.32 –3.09
6317 SERPINB3 –1.83 –5.35 –1.54 –1.74 –2.62 1
2023 ENO1 –1.91 –1.87 –4.20 –2.01 –2.50 2, 3
81688 C6orf62 –1.90 –2.52 –3.01 –1.84 –2.32
102c ADAM10 –2.24 –2.38 –2.82 –1.71 –2.29 1
9749 PHACTR2 –1.61 –3.03 –2.34 –2.13 –2.28
9782 MATR3 –2.34 –2.53 –2.40 –1.81 –2.27 2
4781 NFIB –2.09 –2.56 –2.64 –1.55 –2.21 1
114882 OSBPL8 –2.80 –2.12 –1.87 –1.97 –2.19 2
1545c CYP1B1 –2.62 –2.31 –1.72 –1.99 –2.16 2
3329c HSPD1 –2.53 –1.98 –2.48 –1.58 –2.14 1
89890 KBTBD6 –2.60 –2.10 –1.95 –1.66 –2.08
10914 PAPOLA –1.79 –1.99 –2.53 –1.78 –2.02 3
6772 STAT1 –1.75 –2.70 –2.00 –1.52 –1.99 1
55353 LAPTM4B –1.52 –2.24 –2.59 –1.60 –1.99
2289 FKBP5 –1.68 –2.57 –2.02 –1.67 –1.98 2
829 CAPZA1 –1.88 –1.85 –2.08 –1.99 –1.95 2
5530 PPP3CA –1.84 –1.85 –1.83 –2.21 –1.93 3
55854 LEREPO4 –2.20 –2.22 –1.76 –1.50 –1.92
23002 DAAM1 –1.97 –2.31 –1.75 –1.57 –1.90 2
11137 PWP1 –1.75 –2.29 –1.70 –1.65 –1.85
55055 ZWILCH –1.75 –1.99 –2.03 –1.60 –1.84
9522 SCAMP1 –1.90 –2.06 –1.57 –1.76 –1.82 2
3326 HSP90AB1 –1.68 –1.93 –2.10 –1.51 –1.80 1
27250 PDCD4 –1.57 –2.25 –1.62 –1.74 –1.79 3
5962 RDX –1.76 –1.69 –2.02 –1.69 –1.79 2
1295 COL8A1 –1.80 –1.90 –1.90 –1.50 –1.78 2
64710 NUCKS1 –1.62 –1.71 –1.96 –1.55 –1.71
818 CAMK2G –2.06 –1.59 –1.55 –1.52 –1.68 1
5573 PRKAR1A –1.60 –1.57 –1.91 –1.56 –1.66 1
6595 SMARCA2 –1.68 –1.50 –1.67 –1.56 –1.60 2
636 BICD1 1.51 1.52 1.67 1.70 1.60 2
7779 SLC30A1 1.50 1.70 1.78 1.61 1.65 3
4637 MYL6 1.75 1.58 1.53 1.78 1.66 1
6991 TCTE3 1.70 1.64 1.66 1.96 1.74
26776 RNU71B 1.90 1.71 2.12 1.92 1.91
541466 CT45-1 2.21 1.82 1.58 2.05 1.91
1956c EGFR 2.27 1.92 2.77 2.17 2.28 1
5055c,d SERPINB2 1.84 2.60 1.52 3.18 2.29 1, 3
3576c,d IL8 2.89 3.20 1.86 1.72 2.42 1
101c,d ADAM8 2.70 3.47 2.04 1.62 2.46 3
3598c,d IL13RA2 2.14 2.31 2.18 3.56 2.55 3
3309 HSPA5 2.19 5.92 1.55 1.82 2.87 1, 2
1906c,d EDN1 6.56 2.83 1.54 1.75 3.17 1
4189 DNAJB9 5.14 4.01 1.52 2.09 3.19 2
7718 ZNF165 6.28 3.48 2.04 1.55 3.34
11009c,d IL24 3.43 4.15 2.24 3.57 3.35 1
5743c,d PTGS2 8.68 2.71 1.52 2.17 3.77 1
aThislist includes 48 genes up-regulated or down-regulated by ≥ 1.5-fold at each time point, with a false discovery rate of
< 0.05; IDs are from Entrez Gene (National Center for Biotechnology Information 2008a). bNetworks are as follows: 1,
cardiovascular system development and function, development and function, cellular movement, cancer; 2, cellular
growth and proliferation, hair and skin development and function, cell cycle; 3, immunologic disease, inﬂammatory dis-
ease, tissue morphology. cEleven genes were identiﬁed to have an average of > 2-fold change and directly linked to the
TNF node in the merged three major networks. dSeven of the 11 genes were validated by real-time RT-PCR at most time
points in both Cd- and Cd + TNF Ab–treated groups.
Table 2. Primers used in real-time RT-PCR to validate microarray data.
Gene Forward primer Reverse primer Size (bp)
SERPINB2 CACCCAGAACCTCTTCCTCTCC TAACTGCATTGGCTCCCACTTC 134
IL8 CTCTTGGCAGCCTTCCTGATTT TGGGGTGGAAAGGTTTGGAGTA 115
ADAM8 TGCTCCTCCGGTCACTGTGT ACGTTGGCTTGATGACCTGCT 86
IL13RA2 TCTTGGAAACCTGGCATAGGTG GCCTCCAAATAGGGAAATCTGC 146
EDN1 CTCTCTGCTGTTTGTGGCTTGC GTGGACTGGGAGTGGGTTTCTC 107
IL24 CACACAGGCGGTTTCTGCTATT AAGAATGTCCACTTCCCCAAGG 92
PTGS2 ATTCCCTTCCTTCGAAATGCAA AGAGAAGGCTTCCCAGCTTTTG 117
TNF CTCTTCTGCCTGCTGCACTTTG CAGCTTGAGGGTTTGCTACAACA 157performed in replicates for each of the five
time points (0, 4, 8, 16, 32 hr) with Cd treat-
ment and a no-Cd control. A total of
20 microarrays were used. The data were ana-
lyzed to identify genes whose expression was
altered by Cd treatment at each of four time
points (4, 8, 16, and 32 hr) compared with
the zero time point. Analysis was performed
with R statistical software (R Foundation for
Statistical Computing 2008) and the LIMMA
package for the Bioconductor (Smyth 2004).
We used the rate monotonic algorithm to per-
form all steps of data preprocessing, including
background correction, normalization, and
expression set summaries. Chip quality was
assessed with the affyQCReport package
(Bioconductor 2008). One chip (Cd treat-
ment at 4 hr) was removed from the analysis
because of poor quality. Estimated fold
changes at each time point were calculated by
one-way analysis of variance (ANOVA), and
resulting t-statistics from each comparison
were modiﬁed by an intensity-based empirical
Bayes method (Sartor et al. 2006). Genes for
which all non-zero time points had a false dis-
covery rate < 0.05 were examined according
the fold change of the gene expression in the
four nonzero time points (Table 1). The
results were further scrutinized according to
gene ontology, biological processes, molecular
function, and genetic networks with the aid of
Ingenuity Pathways Analysis (IPA; Ingenuity
Systems, Mountain View, CA). IPA software
maps the biological relationship of uploaded
genes into networks according to published
literature in the database. A relevancy score is
assigned to each network in the data set to
estimate the relevancy of the network to the
gene list uploaded. A higher relevancy score
means that the network is more relevant to the
gene list entered. We selected the three highest
scored networks; genes in these networks were
selected for further post hoc analyses. Top
pathways in each network, if available, were
listed according to their p-values.
Neutralization of TNF. We used puriﬁed
monoclonal TNF neutralization antibody
(TNF Ab, Clone 1825; R&D Systems,
Minneapolis, MN) to neutralize the biologi-
cal activity of TNF. TNF is a multifunc-
tional proinflammatory cytokine secreted
from the cells, which functions through its
receptors. In addition to Cd treatment,
another panel of the cells was co-treated with
4 µg/mL TNF Ab. 
Real-time reverse transcriptase-polymerase
chain reaction (RT-PCR). All primer pairs
were designed to cross at least one intron
(Table 2). Reverse transcription was performed
using SuperScript III (Invitrogen) with 0.5 µg
RNA per 20 µL of reaction mixture. For real-
time PCR, we used the Power Sybr Green kit
(ABI, Foster City, CA) in a 7500 Fast Real-
Time System (ABI) in standard mode. A total
of 0.5 µL cDNA was added to a 20 µL reac-
tion. We used GAPDH and 18S rRNA as the
internal control, as described previously
(Zhang et al. 2007), and found similar results
(data not shown). Real-time RT-PCRs were
performed in quadruplicate and indepen-
dently repeated twice with two sets of cell cul-
tures different from those used in the
microarray. We used the 2–ΔΔCt method with
the tested primers to calculate relative expres-
sion levels of the transcripts; the efficiencies
for the various real-time PCRs were deter-
mined to be close to 100%.
In silico analyses. We retreived the
sequences of the genes from Entrez Gene
(National Center for Biotechnology Informa-
tion 2008a), and information regarding their
genomic organization was obtained by a
BLAT search (UCSC Genome Bioinformatics
2008). Primers were designed with Primer3
(Table 2). Information on the genes are listed
in Table 1.
Statistical analysis. We performed two-
way ANOVA with a Bonferroni post hoc test
on data obtained from the MTS assays, cell-
cycle analyses, and real-time RT-PCR quan-
tification of relative transcript levels. We
considered a p < 0.05 statistically signiﬁcant.
Results
Low-dose CdCl2 exposure increases cell viabil-
ity. The effect of CdCl2 concentrations on the
viability of NPrEC cells was evaluated at dif-
ferent time points (Figure 1). Compared with
the viability of the control with no Cd treat-
ment, which was set as 100%, cell viability
was increased 150–270% after 24, 28, and
72 hr of treatment with 1, 2, 5, or 5 µM
CdCl2. These increases could be due to a pro-
motion of cell growth. However, the viability
of cells exposed to 10 or 20 µM CdCl2 was
enhanced 170–240% during the first 24 hr,
followed by a dramatic loss of cells (> 70%)
after 48 hr, and the death of almost all cells
after 72 hr (~ 98%). Thus, concentrations of
Cd ≥ 10 µM were cytotoxic to NPrEC cells.
Treatment of NPrEC cells with 1, 2.5, or
5 µM CdCl2 for 3 weeks did not elicit a cyto-
toxic response. Compared with the viability in
controls with no Cd treatment, cell viability in
the 1 µM and 2.5 µM Cd-treated cell cultures
exhibited modest increases (~ 20%) in cell via-
bility (data not shown), but no change in cell
viability was observed in cultures exposed to
5 µM Cd compared with controls. Based on
these data, we used the noncytotoxic, growth-
promoting concentration of 2.5 µM CdCl2
for subsequent experiments.
Biphasic effects of Cd in cell cycle progres-
sion. We evaluated the effect of 2.5 µM CdCl2
on cell-cycle distribution of NPrEC cells after
cells were synchronized by supplement depri-
vation for 72 hr (Figure 2). The synchroniza-
tion technique reduced the background noise
in cell cycle analyses but was not expected to
affect cell growth or death induced by the Cd
treatment per se. Compared with the control
cells with no Cd treatment, cells exposed to
Cd for 8 hr showed an increase in the G1
phase (from 63.1% to 72.0%) and a reduction
in cells in the S phase (from 21.0% to 11.4%)
(Figure 2). However, cells treated longer
(32 hr) progressed through the cell cycle faster
than did the control, resulting in an increase
in cells in the G2 phase (27.5% of treated cells
vs. 15.3% of control) and a decrease in cells in
the G1 phase (63.7% of the treated cells vs.
53.4%). Our ﬂow cytometry data indicated a
transient blockage of cell-cycle progression at
8 hr, followed by acceleration after NPrEC
cells were exposed to Cd 32 hr. Notably, the
sub-G1 peak, an indication of apoptosis, is not
evident in Figure 2. 
Transcriptome and gene ontology analyses.
We assessed the effects of CdCl2 on changes in
gene expression at 4, 8, 16, and 32 hr after
exposure to Cd by global transcriptional pro-
ﬁling using a whole genome array with 54,675
probe sets (Figure 3). Forty-eight known genes
(excluding three duplicate genes, two hypo-
thetical genes, and two unknown genes) were
differentially expressed in the control and
Cd-treated cultures for all four time points
investigated in the microarray data (Table 1).
This initial “cutoff” criterion was chosen based
on our experiences (Syed et al. 2005; Tam
et al. 2008); changes in gene expression
< 1.5-fold are difﬁcult to be validated by real-
time RT-PCR. We conducted gene ontology
Transcriptome analysis in Cd-treated prostatic epithelial cells
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Figure 1. Effect of CdCl2 on viability of NPrEC cells
treated with different concentrations of CdCl2 for
24 (A), 48 (B), or 72 (C) hr. Cell viability was deter-
mined by MTS assay. Each time point represents the
mean value of quadruplicates ± SD. 
*p < 0.05. **p < 0.01. #p<0.001. 
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(input: 48 genes). Genes were mapped princi-
pally to three major networks (Figure 4A)
with the highest relevancy scores: a) cardio-
vascular system development and function,
cellular movement, and cancer; b) cellular
growth and proliferation, hair and skin devel-
opment and function, and cell cycle; and
c) immunologic disease, inﬂammatory disease,
and tissue morphology. Because of overlaps of
the three networks, we used IPA to merge
them to a larger network containing 35 of the
original 48 genes (Figure 4B).
Validation of transcriptome profiling
data. Fourteen genes were identified by IPA
to have a known connection to TNF
(Figure 4C). Eleven of them exhibited an
average of ≥ 2-fold change in microarray
signals for four time points following
Cd-treatment (Table 1, footnote c). Real-time
RT-PCR conﬁrmed that Cd induced an up-
regulation of prostaglandin-endoperoxide
synthase 2 (COX-2/PTGS2), ADAM metallo-
peptidase domain 8 (ADAM8), endothelin 1
(EDN1), serpin peptidase inhibitor, clade B
(ovalbumin), member 2 (SERPINB2), inter-
leukin 24 (IL24), IL8, and interleukin 13
receptor, alpha 2 (IL13RA2) (Figure 5) at
most time points. Of the 28 pairs of compari-
son groups (control and Cd-treated, 7 genes
at four time points; total of 56 groups),
23 pairs of comparison groups (82%) exhib-
ited differences at a significance of p < 0.05
and 21 groups (75%) at p < 0.001. This
demonstrated a high degree of concordance
between the microarray data and the quantiﬁ-
cation by real-time RT-PCR. Cd also induced
a down-regulation of cytochrome P450B1
(CYP1B1) ADAM10, HSPD1, and STAT1.
Real-time RT-PCR validated the down-regu-
lation of these genes at two time points (data
not shown). Furthermore, among the genes
shown in Figure 4B, we had picked three
genes—SERPINB3, HSPA5, and DNAJB9—
for real-time PCR validation and were able to
confirm same direction of change at three
time points as the microarray data (data not
shown). The latter finding further demon-
strated the effectiveness of identification of
gene/network by global transcription proﬁling
combined with knowledge-based analyses.
Bakshi et al.
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Figure 3. A schematic diagram illustrating the strategies and approaches used
in candidate identiﬁcation, gene shaving, knowledge-based analysis, and vali-
dation of a Cd-induced, TNF-regulated transcriptome in NPrEC cells. 
Cd-treated NPrEC cells
harvested at 0, 4, 8, 16, and 32 hr
Global transcriptional profiling
4 time points, 48 genes 4,  8, 16, and 32 hr individually
Knowledge-based analysis: Figure 4A
Gene shaving: exclude minor networks
Merged into a single network: Figure 4B
Knowledge-based analysis: Figure 4C
IPA
3 major networks
35 genes
IPA
Top pathways
16 and 32 hr
TNF
is the largest
node
14 genes
11 genes
Gene shaving: genes connect to TNF
Gene shaving: selected candidates with
an average expression changes > 2-fold
Validation of TNF
transient up-regulation
4 and 8 hr
Same pattern
Cd-induced
gene expression
TNF Ab blocked
Cd action
Validated: PTGS2, ADAM8, EDN1,
SERPINB2, IL8, IL24, and IL13RA2
All related
to TNF
Figure 6
Figure 5
Figure 5
Gene shaving:
≥ 1.5-fold changes;
false discovery rate < 0.05
Figure 2. Effect of CdCl2on cell-cycle distribution in NPrEC cells determined by ﬂow
cytometry analysis. (A) Fluorescence analysis of the DNA content. (B) Cd-induced
change of the cell phase. The sub-G1 peak, an indication of apoptosis, is not
shown. Fluorescence-2 area (FL2-A) is a measure of integrated cell ﬂuorescence
signal that represents the DNA content. Data represent results from two replicates. 
*p < 0.05. **p < 0.01. 
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32 hrTNF plays a central role in Cd-induced
alteration of gene expression. To determine if
TNF mediates the action of Cd in regulating
the genes in the demonstrated network, we
first showed a 28-fold transient increase in
the accumulation of TNF transcripts after
4 hr of Cd exposure (Figure 5). We then co-
treated NPrEC cultures with Cd plus
TNF Ab and observed signiﬁcant blockade of
the Cd-induced up-regulation of all seven
genes at most time points following the co-
treatment. Of the 14 pairs of comparison
groups (28 individual groups; Cd and Cd +
TNF Ab) at 8 and 16 hr, signiﬁcant blockade
of the Cd-induced gene alteration by
TNF Ab was exhibited in 13 pairs of com-
parison groups (93%) at p < 0.05 and
10 groups (71%) at p < 0.001. At 32 hr,
however, we observed no significant differ-
ences between the Cd-treated and the Cd +
TNF Ab–treated cultures, which is consistent
with the ﬁnding of no signiﬁcant increase in
TNF transcripts in Cd-treated cultures at this
late stage. However, the down-regulation of
CYP1B1 by Cd exposure was not reversed by
the addition of TNF Ab to the culture
medium (data not shown). 
Microarray and pathway analysis at indi-
vidual time points. We were concerned that
we may have lost valuable information because
of our initial gene-shaving strategy of includ-
ing only genes that displayed ≥ 1.5-fold
change across all four time points. To address
this concern, we reanalyzed the microarray
data in a different manner. We identified
genes affected by Cd treatment (≥ 1.5-fold
changes and false discovery rate < 0.05) at
each time point: for 4, 8, 16, and 32 hr of Cd
treatment, we identiﬁed 2,211, 1,995, 1,871,
and 1,087 genes, respectively. When these
gene sets were individually analyzed with IPA,
the top pathway identiﬁed for each of the four
time points was invariably one that was con-
nected to TNF (Figure 6). Importantly, we
found the same seven genes to be connected to
TNF at each of the four time points: COX-
2/PTGS2, ADAM8, EDN1, SERPINB2,
IL24, IL8, and IL13RA2. These were the same
genes identiﬁed earlier using our initial gene-
shaving strategies (Figure 3), and they were
confirmed to be up-regulated by Cd and
responsive to TNF-neutralizing antibody
reversal (Figure 5). At 16 and 32 hr of Cd-
treatment, an additional seven genes were
found to be linked to TNF, yielding a total of
14 genes in the network. Interestingly, these
14 genes were identical to those shown in
Figure 4C, which shows a network identiﬁed
using the initial gene-shaving criteria. These
findings collectively removed the concern of
potential limitation of our initial gene-shaving
strategy. Furthermore, they have strengthened
our claim that the effect of Cd on NPrEC was
mediated by TNF. 
Discussion
Unequivocally, Cd is a carcinogen for the rat
prostate, but its oncogenic action on the
human gland remains debatable (Waalkes
2003). Recent investigations have demon-
strated that the metal ion could induce neo-
plastic transformation of human prostatic
epithelial cells (Achanzar et al. 2001; Nakamura
et al. 2002) that is accompanied by evasion of
apoptosis (Qu et al. 2007). However, the
mechanisms underlying the initiation of car-
cinogenesis by Cd in the human prostate are
still not fully understood. Emerging evidence
now indicates a strong association between
chronic prostatic inflammation and human
PCa (Sciarra et al. 2007). Cd is excreted at a
rate of approximately 0.001%/day; therefore, it
accumulates in the body for decades (Satarug
and Moore 2004). An age-dependent increase
in body burden of Cd and chronic exposure of
the prostate to Cd may promote persistent
inflammation, which is associated with
increased cell proliferation and evasion of
apoptosis, favoring neoplastic transformation
in the prostate. 
Immortalized normal prostate epithelial
cell lines such as NPrEC are a useful model for
the study of early events underlying prostate
Transcriptome analysis in Cd-treated prostatic epithelial cells
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Figure 4. Pathway analysis of genes differentially expressed by microarray in Cd-treated NPrEC cells. When
the 48 genes (Figure 3, Table 1) were input into IPA, it mapped them to three networks with high relevancy
scores and four networks of low scores (A). The three high score networks were merged into a single net-
work with 35 genes (B), with TNF as the largest node connected to 14 genes (C). The score indicates the
degree of relevance of a network to the molecules in the input data set, which takes into account the num-
ber of network-eligible genes and the size of the network. Additional information is available at the IPA
website (Ingenuity Systems 2008). The brighter the color of the gene, the higher the fold changes.
*Multiple identiﬁers in the array data set ﬁle map to a single gene. 
Cytokine
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Kinase
Transcription regulator
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Inhibit and acts on
Direct interaction
Indirect interaction
A
B
Ccarcinogenesis. We exposed synchronized
NPrEC cells to different concentrations of Cd
and found that low levels of CdCl2 (≤ 5µ M )
consistently increased cell viability but that
higher levels inevitably led to cell demise with
72 hr of exposure. A similar biphasic response
has been reported previously (Achanzar et al.
2000). The mitogenic response to low-dose
Cd appeared to involve a transient blockage of
cell-cycle progression at 8 hr, followed by
acceleration through the cycle. These changes
suggested major changes in the NPrEC
expression transcriptome that might provide a
mechanistic explanation for Cd-induced neo-
plastic transformation of normal prostate
epithelial cells. With this rationale in mind,
we exposed synchronized NPrEC cell cultures
to a low-dose of Cd (2.5 µM) and investigated
changes in global gene expression over time.
We used a stringent gene-shaving strategy
coupled with knowledge-based analyses to
uncover changes in gene expression most 
relevant to biological responses. We have iden-
tiﬁed, for the ﬁrst time, that TNF is the most
prominent node in a network of Cd-regulated
genes related to immunomodulations, oncoge-
nesis, cell proliferation, and apoptosis. Among
the seven up-regulated genes identiﬁed to be
linked to TNF, real-time RT-PCR validated
three genes that were changed >2-fold across at
all four time points, three across three time
points, and one at two time points. Further-
more, Cd exposure dramatically increased
TNF expression (28-fold) during the early
stage (4 hr); this in turn led to an up-regulation
of seven genes in the later stage of response
(8–16 hr). Most important, when we used a
TNF-neutralizing antibody to negate the
autocrine effects of the cytokine in NPrEC cul-
tures, the up-regulation of seven genes by Cd
was blocked, providing strong evidence that
these genes are downstream targets of TNF.
Anti-TNF monoclonal antibodies have also
been used in patients for anti-TNF treatment
(Shealy and Visvanathan 2008). It should be
noted that our initial analyses of the microarray
data did not identify TNF as a target gene
whose expression was signiﬁcantly altered by
Cd. In this regard, knowledge-based analysis
has certainly added a new strategic dimension
to the analysis of microarray data. These ﬁnd-
ings collectively illustrated a high degree of
validity of using a combined approach of
global transcription proﬁling and knowledge-
based analysis for gene network discovery.
Although Cd cannot form stable DNA
adducts and is not a redox-active metal
(Waalkes 2000), the induction of TNF and its
downstream target genes could lead to muta-
genic changes necessary for the development
of epithelial cancers (Babbar and Casero
2006). TNF is a cytokine involved in systemic
inﬂammation with a primary role of regulat-
ing immune cells. For instance, exposure of
Bakshi et al.
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Figure 5. Validation of microarray data and investigation of the role of TNF in Cd-treated NPrEC cells. Real-
time RT-PCR conﬁrmed the up-regulation of 7 of the 11 TNF-related genes inferred by IPA. It also demon-
strated a transient increase in TNF mRNA expression following Cd treatment. Each time point represents
the mean value of quadruplicates ± SD. Two-way ANOVA compared Cd-treated group with control and Cd
+ Ab group, respectively. 
*p < 0.05. **p < 0.01. #p < 0.001. 
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Figure 6. Pathway analysis of genes differentially expressed at each of the four time points. At 4 and 8 hr
of Cd treatment, genes exhibited in the top pathway were the same eight genes conﬁrmed by real-time RT-
PCR (Figure 5). With longer Cd exposure at 16 and 32 hr, the top pathway exhibited the same pattern as
shown in Figure 4C. The brighter the color of the gene, the higher the fold changes.
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Direct interaction
Indirect interactionhuman bronchial epithelial cells to TNF was
found to increase intracellular reactive oxygen
species via an induction of spermine oxidase
and to lead to oxidative DNA damage, as
indicated by the accumulation of 8-oxo-
deoxyguanosine in cell nuclei (Babbar and
Casero 2006). If a parallel could be drawn for
NPrEC, Cd-induced overexpression of TNF
and its associated autocrine signaling could
lead to the mutagenic changes necessary for
neoplastic transformation. 
Of the seven TNF-up-regulated genes iden-
tiﬁed, PTGS2 (COX-2) is involved in inﬂam-
mation-mediated oxidative stress favoring
prostatic carcinogenesis (Tam et al. 2007). This
enzyme is overexpressed in human prostate ade-
nocarcinoma, and its inhibitors hold promise
for PCa prevention and therapy (Hussain et al.
2003). ADAM8 is a catalytically active metallo-
proteinase with a purported role in the degrada-
tion of the vascular basement membrane
(Handsley and Edwards 2005). The over-
expression of ADAM8 in PCa is associated with
parameters of unfavorable prognosis (Fritzsche
et al. 2006). EDN1, the most potent vaso-
constrictor known, acts as a survival factor for
endothelial cells. Within the prostate, EDN1 is
mainly epithelial, while its receptors are present
in the stroma and epithelium. EDN1 is ele-
vated in the plasma of patients with hormone-
refractory PCa and stimulates osteoblastic
remodeling, suggesting a role in the develop-
ment of bone metastases (Granchi et al. 2001).
EDN1 is suspected to act as an autocrine factor
during malignant transformation (Granchi
et al. 2001). It is overexpressed in PCa and
inhibits apoptosis (Godara et al. 2007). The
up-regulation of EDN1 in Cd-treated NPrEC
cells is consistent with the observation that no
sub-G1 peak was observed in the ﬂow cytome-
try result (Figure 2). IL8 is a powerful chemo-
tactic factor that provides a growth advantage
to tumor cells. In particular, IL8 expression in
the prostate correlates positively with tumor
progression and cell dedifferentiation (Lee et al.
2004), and its levels are higher in the serum of
patients with metastatic PCa (Murphy et al.
2005). A parallel increase in IL8 and its recep-
tors has been associated with proliferation and
microvessel density in PCa. Thus, IL8 in the
prostate have been deemed responsible for PCa
initiation and promotion (Murphy et al. 2005).
IL13RA2, one of the components of the type I
IL13R, is frequently expressed on the surface of
different cancer cells (Kawakami 2005).
Expression of IL13RA2 is high in ovarian can-
cer but very low in the normal ovary (Kioi et al.
2006). IL13RA2 dramatically enhances the
antitumor effect of IL13 receptor–targeted
cytotoxin in human PCa xenografts (Kawakami
et al. 2001). Meanwhile, no direct studies have
reported a role of SERPINB2 and IL24 in PCa. 
SERPINB2 has been shown to inhibit
urokinase-type plasminogen activator, which
is expressed at higher levels in PCa tissues
(Wang and Jensen 1998); Delivery of IL24 to
the cells profoundly inhibits PCa cell growth
(Sarkar et al. 2007). The overexpression of
SERPINB2 and IL24 may be an attempt by
NPrEC cells to guard against the unfavorable
Cd challenge. 
We also conducted an exhaustive literature
search and found that six of seven genes found
to be connected to TNF by IPA analyses had
previously been reported to be regulated by
TNF at the promoter, transcript, or protein
level: PTGS2 (Chen et al. 2000; Ikawa et al.
2001; Subbarayan et al. 2001), IL8 (Lora et al.
2005; Rathanaswami et al. 1993; Treede et al.
2007), EDN1 (Woods et al. 2003), ADAM8
(Schlomann et al. 2000; Banno et al. 2004),
IL13RA2 (David et al. 2003), and SERPINB2
(Wang and Jensen 1998). These documented
connections between TNF and genes identiﬁed
in this study further solidify our belief of the
existence of such a network in NPrEC cells.
In the ﬁrst step in our initial gene-shaving
scheme, the genes for knowledge-based analy-
ses were limited to those that were signiﬁcantly
changed at all four treatment time points. This
stringent criterion might ﬁlter out potentially
valuable information due to the limited num-
ber of genes included. With this concern in
mind, knowledge-based analyses were also per-
formed using microarray data collected at indi-
vidual time points. Using this approach, we
consistently identiﬁed a TNF-network as the
top network linking genes affected by Cd-
treatment of NPrEC cells, and we found that
the genes connected to this TNF-network were
identical to the genes discovered using our ini-
tial criteria. These ﬁndings inspire conﬁdence
in our original strategy scheme for data analysis
and lend credence to our claim that TNF is an
early mediator of Cd-action on NPrEC cells. 
In summary, using NPrEC cells as a
model, we have identiﬁed for the ﬁrst time a
TNF-associated network that is responsive to
low-dose Cd exposure. Genes in this network
are involved primarily in inflammation and
immunomodulation that are linked to car-
cinogenesis. Identification of this regulatory
pathway has shed new light on the mechanism
of Cd-mediated prostate carcinogenesis that
may involve a transient, “intrinsic” overexpres-
sion of TNF in the prostatic epithelium.
Finally, this study represents one of those rare
success in which global transcriptional proﬁl-
ing was able to formulate a novel hypothesis
that was subsequently tested. 
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